Claims
- 1. A pharmaceutical composition comprising a therapeutically effective amount of:
- 2. A pharmaceutical composition according to claim 1 comprising a pharmaceutically acceptable carrier and from about 250 mg to about 5000 mg of a benzimidazole selected from the group consisting of:
- 3. A pharmaceutical composition according to claim 2 wherein said benzimidazole is methyl-(butylcarbamoyl)-2-benzimidazolecarbamate or 2-methoxycarbonyl-aminobenzimidazole.
- 4. A pharmaceutical composition according to claim 1 wherein said pharmaceutical acceptable acid addition salts are selected from the group consisting of chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates and mixtures thereof.
- 5. A pharmaceutical composition according to claim 4 comprising from about 500 mg to about 5000 mg of said benzimidazole.
- 6. A pharmaceutical composition according to claim 5 wherein said salt is a hydrochloride salt.
- 7. A pharmaceutical composition according to claim 1 wherein said adjunct therapy comprises a member selected form the group consisting of protease inhibitors, AZT, 3TC, ddC, dd1, thiabendazole, (5-aryl-1,2,4-thiadiazol)-3-yi thiourea, N-chlorophenylcarbamates and N-chlorophenylthiocarbarnates, and mixtures thereof.
- 8. A pharmaceutical composition according to claim 1 wherein the ratio of benzimidazole to adjunct therapy is from about 1:0.001 to about 1:1.
- 9. A method of treating HIV comprising administering therapeutically effective amount of a benzimidazole of the formula:
- 10. A method according to claim 9 comprising from about 100 mg to about 6000 mg of said benzimidazole having the formula:
- 11. A method according to claim 9 wherein said benzimidazole is selected from the group consisting of methyl-(butylcarbamoyl)-2-benzimidazolecarbamate or 2-methoxycarbonyl-aminobenzimidazole.
- 12. A method according to claim 11 wherein said pharmaceutical acceptable acid addition salts are selected from the group consisting of chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates and mixtures thereof.
- 13. A method according to claim 10 wherein said composition is in a liquid form, and wherein said liquid dosage form is selected from the group consisting of aqueous solutions, emulsions, suspension solutions, and suspensions reconstituted from non-effervescent and effervescent preparations.
- 14. A method according to claim 13 wherein said liquid dosage form further comprises a member selected from the group consisting of suspending agents, diluents, sweeteners, flavorants, colorants, preservatives, emulsifying agents and coloring agents, and mixtures thereof.
- 15. A method of treating HIV infections comprising administering a therapeutically effective amount of an adjunct therapy in combination with a benzimidazole of the formula:
- 16. A method according to claim 17 wherein said adjunct therapy comprises a member selected from the group consisting of AZT, TC-3, protease inhibitors, thiabendazole, N-chlorophenylcarbamates, N-chlorophenylthiocarbamates or (5-aryl-1,2,4-thiadiazolyl)-thioreas.
- 17. A method according to claim 16 wherein said benzimidazole is administered in a solid form and wherein said solid form includes a carrier selected from the group consisting of lactose, sucrose, gelatin and agar.
- 18. A method according to claim 17 wherein from about 1500 mg/kg to about 5000 mg/kg of said benzimidazole is administered.
- 19. A method according to claim 18 wherein said benzimidazole is administered in a liquid form and wherein said liquid dosage form is selected from the group consisting of aqueous solutions, alcohol solutions, emulsions, suspensions, and suspensions reconstituted from non-effervescent and effervescent preparations and suspensions in pharmaceutically acceptable fats or oils.
- 20. A method according to claim 16 wherein said adjunct therapy is selected from the group consisting of ACT, TC-3, or protease inhibitors.
Parent Case Info
[0001] The present application is a continuation application of U.S. Ser. No. 09/703,955 filed Nov. 1, 2000, incorporated by reference herein, and claims priority to said application under 35 U.S.C. §120.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09703955 |
Nov 2000 |
US |
Child |
10280100 |
Oct 2002 |
US |